Search clinical trials for: IMVAMUNE (MVA-BN)

Total 6003 results

Bavarian Nordic
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

A Phase II Study on Immunogenicity and Safety of MVA-BN® (IMVAMUNE™) Smallpox Vaccine in Subjects With Atopic Dermatitis

Atopic Dermatitis

United States, Mexico
Bavarian Nordic
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Safety, Tolerability and Immune Response of IMVAMUNE (MVA-BN)Smallpox Vaccine in HIV Infected Patients

HIV Infections

United States
Bavarian Nordic
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Dose-finding Study to Evaluate Immunogenicity of Three Different Dose Levels of the IMVAMUNE (MVA-BN) Smallpox Vaccine.

Smallpox

Switzerland
Bavarian Nordic
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Safety, Tolerability and Immune Response of IMVAMUNE (MVA-BN)Smallpox Vaccine in Patients With Atopic Disorders

Dermatitis, Atopic | Hay Fever

Germany
Bavarian Nordic
National Institutes of Health (NIH)

Completed

Safety and Immunogenicity of IMVAMUNE® (MVA-BN®) Smallpox Vaccine in HIV Infected Patients

HIV Infections

United States, Puerto Rico
Bavarian Nordic
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

A Randomized, Double-blind, Placebo-controlled Study on Immunogenicity and Safety of MVA-BN (IMVAMUNE™) Smallpox Vaccine in Healthy Subjects

Smallpox

Germany
Bavarian Nordic
US Army Medical Research Institute of Infectious Diseases

Completed

A Non-inferiority Trial to Compare MVA-BN® Smallpox Vaccine to ACAM2000®

18-42 Year Old Healthy Vaccinia-naïve Subjects

Korea, Republic of
Bavarian Nordic
JPM CBRN Medical

Completed

Vaccination Trial of a Recombinant MVA-BN-WEV Vaccine in Healthy Adult Subjects

Equine Encephalitis

United States
Bavarian Nordic

Completed

A Trial to Evaluate Immunogenicity and Safety of Three Consecutive Production Lots of IMVAMUNE® (MVA-BN®) Smallpox Vaccine in Healthy, Vaccinia-naïve Subjects

Smallpox

United States
Bavarian Nordic

Completed

Study on Safety, Tolerability and Immunogenicity of an MVA Vaccine Administered to Healthy Subjects

Smallpox

Germany
Bavarian Nordic

Completed

Trial to Evaluate the Safety, Tolerability and Immunogenicity of the Recombinant MVA BN® RSV Vaccine

Respiratory Syncytial Virus Infections

United States
Bavarian Nordic

Completed

A Phase 1 Open Label Trial of Intravenous Administration of MVA-BN-Brachyury Vaccine in Patients With Advanced Cancer

Solid Metastatic Tumor

United States
Bavarian Nordic

Completed

A Safety and Immunology Study of a Modified Vaccinia Vaccine for HER-2(+) Metastatic Breast Cancer

Breast Cancer

United States
Bavarian Nordic

Completed

A Safety and Immunology Study of a Modified Vaccinia Vaccine for HER-2(+) Breast Cancer After Adjuvant Therapy

Breast Cancer

United States
Bavarian Nordic

Completed

A Safety Trial of MVA-BN®-PRO in Men With Androgen-Insensitive Prostate Cancer (BNIT-PR-001)

Androgen-insensitive Prostate Cancer

United States
Bavarian Nordic
Biomedical Advanced Research and Development Authority

Completed

Freeze-Dried MVA-BN® Lot Consistency Smallpox Trial

Smallpox

United States
Bavarian Nordic

Withdrawn

RSV-MVA-BN Vaccine Phase I Trial, Intranasal Application in Adults.

Respiratory Syncytial Virus Infections
MRC/UVRI and LSHTM Uganda Research Unit
Epicentre, Paris, France.; Janssen Pharmaceutica N.V., Belgium; Coalition for... and other collaborators

Completed

ZEBOVAC (Ebola Vaccine Trial, Ad26.ZEBOV/MVA-BN-Filo)

Ebola Virus Disease

Uganda
Bavarian Nordic

Completed

RSV-MVA-BN Vaccine Phase II Trial in ≥ 55 Year Old Adults

Respiratory Syncytial Virus Infections

United States
Bavarian Nordic

Completed

Randomized, Open-label Phase II Trial to Assess the Safety and Immunogenicity of MVA-BN Smallpox Vaccine in Immunocompromised Subjects With HIV Infection

Smallpox

United States, Puerto Rico
Bavarian Nordic

Completed

Safety and Tolerability Trial (MVA-BN-Brachyury/FPV-Brachyury)

Safety Issues

United States
National Institute of Allergy and Infectious Diseases...

Completed

Safety, Reactogenicity and Immunogenicity of MVA in Hematopoietic Stem Cell Transplant (HSCT) Subjects

Variola Major (Smallpox)

United States
University of Utah
Genentech, Inc.; Bavarian Nordic

Withdrawn

Perioperative Atezolizumab With MVA-BN-Brachyury and PROSTVAC For Intermediate-Risk And High-Risk Localized Prostate Cancer (AtezoVax)

Prostate Adenocarcinoma

United States
Janssen Vaccines & Prevention B.V.
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

A Study to Evaluate Safety, Tolerability, and Immunogenicity of Heterologous Prime-boost Regimens Using the Multivalent Filovirus Vaccines Ad26.Filo and MVA-BN-Filo Administered in Different Sequences and Schedules in Healthy Adults

Healthy

United States
Centers for Disease Control and Prevention
Bavarian Nordic; Kinshasa School of Public Health; Ministry of Public Health,...

Active, not recruiting

JYNNEOS Smallpox Vaccine in Adult Healthcare Personnel at Risk for Mpox in the Democratic Republic of the Congo

Monkeypox Virus Infection

Congo, The Democratic Republic of the
University of Oxford
National Institute of Allergy and Infectious Diseases (NIAID); Wellcome Trust

Completed

A Study to Assess New Ebola Vaccines, cAd3-EBO Z and MVA-BN® Filo

Ebola | Ebola Zaire

United Kingdom
Janssen Vaccines & Prevention B.V.
Institut National de la Santé Et de la Recherche Médicale, France; Centre Muraz and other collaborators

Completed

Safety, Tolerability and Immunogenicity Study of 3 Prime-boost Regimens for Ebola Vaccines Ad26.ZEBOV/MVA-BN-Filo in Healthy Adults, Children and Human Immunodeficiency Virus Positive (HIV+) Adults

Hemorrhagic Fever, Ebola

Kenya, Uganda, Burkina Faso, Côte D'Ivoire
Janssen Vaccines & Prevention B.V.
Walter Reed Army Institute of Research (WRAIR)

Completed

Safety, Tolerability and Immunogenicity Study of 2-dose Heterologous Regimens for Ebola Vaccines Ad26.ZEBOV/MVA-BN-Filo

Hemorrhagic Fever, Ebola

United States, Uganda, Kenya, Mozambique, Nigeria, Tanzania
Crucell Holland BV

Completed

A Safety and Immunogenicity Study of Heterologous Prime-Boost Ebola Vaccine Regimens in Healthy Participants

Healthy

United Kingdom
London School of Hygiene and Tropical Medicine
Public Health England; Janssen Vaccines & Prevention B.V.; Epicentre; Coalition... and other collaborators

Active, not recruiting

Effectiveness and Safety of a Heterologous, Two-dose Ebola Vaccine in the DRC

Ebola Virus Disease

Congo, The Democratic Republic of the
Janssen Vaccines & Prevention B.V.
Institut National de la Santé Et de la Recherche Médicale, France; University...

Completed

A Study to Assess Safety, Tolerability, and Immunogenicity of Three Heterologus 2-dose Regimens of the Candidate Prophylactic Vaccines for Ebola in Healthy Adults

Ebola Viral Disease

France, United Kingdom
Janssen Vaccines & Prevention B.V.
Emory University; Coalition for Epidemic Preparedness Innovations; Center for...

Completed

A Study of a 2-dose Ebola Vaccine Regimen of Ad26.ZEBOV Followed by MVA-BN-Filo in Healthy Pregnant Women (INGABO)

Healthy

Rwanda
Janssen Vaccines & Prevention B.V.

Completed

A Safety and Immunogenicity Study of Heterologous and Homologous Prime-Boost Ebola Vaccine Regimens in Healthy Participants

Healthy

United States
Crucell Holland BV

Completed

A Study to Evaluate the Safety and Immunogenicity of Heterologous Prime-Boost Ebola Vaccine Regimens in Healthy Participants

Healthy

Kenya
Crucell Holland BV

Completed

A Study to Assess the Safety and Immunogenicity of Heterologous Prime-Boost Ebola Vaccine Regimens in Healthy Participants

Healthy

Tanzania, Uganda
National Cancer Institute (NCI)

Active, not recruiting

Phase I/II Trial Investigating the Safety, Tolerability, Pharmacokinetics, Immune and Clinical Activity of SX-682 in Combination With BinTrafusp Alfa (M7824 or TGF-beta "Trap"/PD-L1) With CV301 TRICOM in Advanced Solid Tumors (STAT)

Metastatic Cancer | Solid Tumors

United States
National Institute of Allergy and Infectious Diseases...

Completed

A Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of MVA-BN Yellow Fever Vaccine With and Without Montanide ISA-720 Adjuvant in 18-45 Year Old Healthy Volunteers

Yellow Fever | Yellow Fever Immunisation

United States
Janssen Vaccines & Prevention B.V.
London School of Hygiene and Tropical Medicine; Institut National de la Santé... and other collaborators

Completed

Staged Phase 3 Study to Assess the Safety and Immunogenicity of Ebola Candidate Vaccines Ad26.ZEBOV and MVA-BN-Filo (EBOVAC-Salone)

Ebola Virus Disease

Sierra Leone
Alexion Pharmaceuticals, Inc.

Recruiting

Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN) (ICAN)

Immunoglobulin A Nephropathy | IgAN

Spain, United Kingdom, United States, Italy, Korea, Republic of, Belgium, Germany, Colombia, Japan, China, France, Saudi Arabia, Thailand, Australia, Canada, Brazil, Malaysia, Poland, Taiwan, Austria, Greece, Israel, Netherlands, Arge... and more
National Institute of Allergy and Infectious Diseases...
London School of Hygiene and Tropical Medicine; Institut National de la Santé... and other collaborators

Active, not recruiting

Partnership for Research on Ebola VACcinations (PREVAC)

Ebola Virus Disease

Guinea, Liberia, Mali, Sierra Leone
Bavarian Nordic
National Institutes of Health (NIH)

Completed

Single-Blind, Controlled Safety and Immunogenicity Study of Recombinant MVA Virus to Treat HIV Infection

HIV Infections

Germany
Bavarian Nordic
National Institutes of Health (NIH)

Completed

An Evaluation of Immunogenicity and Safety of Two Doses of MVA-nef vs. MVA-BN in HIV-1 Infected Patients

HIV Infection

Germany
University of Maryland, Baltimore
National Institute of Allergy and Infectious Diseases (NIAID); Wellcome Trust; Leidos Biomedical Research, Inc...

Completed

Phase 1 Trial of Ebola Vaccine in Mali

Ebola Virus Disease | Hemorrhagic Fever

Mali
Alexion Pharmaceuticals, Inc.

Recruiting

Ravulizumab in Thrombotic Microangiopathy After Hematopoietic Stem Cell Transplant

Thrombotic Microangiopathy

United States, Italy, Spain, Korea, Republic of, United Kingdom, Belgium, Netherlands, Germany, Japan, Greece, Brazil, Israel, France, China, Sweden, Australia, Canada, Poland
Patrick Boland
Bristol-Myers Squibb; Hoosier Cancer Research Network; Bavarian Nordic

Active, not recruiting

A Trial of Perioperative CV301 Vaccination in Combination With Nivolumab and Systemic Chemotherapy for Metastatic CRC

Metastatic Colorectal Cancer

United States
Ivan Litvinov

Terminated

Imvamune Vaccine for the Treatment of Non-melanoma Skin Cancer (MUSIC-01)

Basal Cell Carcinoma | Squamous Cell Carcinoma | Non-melanoma Skin Cancer

Canada
National Institute of Allergy and Infectious Diseases...
Institut National de Recherche Biomédicale. Kinshasa, République Démocratique...

Recruiting

Assessment of Safety Profile of MVA-BN Vaccine in the PALM-007 Study in DRC

Monkeypox

Congo, The Democratic Republic of the
Massachusetts General Hospital

Terminated

Secretin Enhanced MRCP for Evaluation of Pancreatic Duct in Pediatric Population

Chronic Pancreatitis | Acute Recurrent Pancreatitis

United States
Repligen Corporation

Completed

Synthetic Human Secretin in Children With Autism

Autism

United States
Janssen Vaccines & Prevention B.V.

Completed

A Study to Evaluate A Range of Dose Levels of Ad26.ZEBOV and MVA-BN-Filo in Healthy Adult Participants

Healthy

United States

Search clinical trials for: IMVAMUNE (MVA-BN)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Jamaica

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations